Development of Blood Protein Biomarkers for Neuromuscular Disorders
From Discovery to Practical Application
Time: Fri 2026-10-23 10.00
Location: Gradängsalen, Teknikringen 1, Stockholm
Video link: https://kth-se.zoom.us/j/63278097567
Language: English
Subject area: Biotechnology
Doctoral student: Albert Jiménez-Requena , Proteinvetenskap
Opponent: Prof. Masood Kamali-Moghaddam,
Supervisor: Professor Cristina Al-Khalili Szigyarto, Proteinvetenskap; Assoc. Prof. Pietro Spitali,
QC 2026-09-24
Abstract
Rare neuromuscular disorders are genetically defined but clinically heterogeneous, and their slow and variable progression is difficult to capture in short clinical studies. Clinical assessment, imaging and muscle biopsy provide essential information but do not fully meet the need for repeatable molecular measures of disease progression and therapeutic response. Blood proteins are attractive biomarker candidates, yet their interpretation depends on the disease context, longitudinal behaviour, analytical platform, molecular form detected and intended context of use.
This thesis developed a staged strategy for blood-protein biomarker develop- ment using Duchenne muscular dystrophy (DMD) and Limb-girdle muscular dystrophy R2 (LGMD R2), a dysferlin-related disease, as complementary models. Suspension bead arrays and SomaScan were used for high-plex discovery and longitudinal evaluation, followed by cross-cohort and orthog- onal confirmation, sandwich-immunoassay development and targeted liquid chromatography-tandem mass spectrometry.
Initial studies focused on the identification of disease monitoring biomarkers. In LGMD R2, analysis of 698 serum samples from 110 participants in the Jain Clinical Outcome Study identified seven candidate biomarkers associated with disease status, muscle MRI, functional performance or progression-related variables. A seven-protein panel showed predictive performance for clinically meaningful decline in six-minute walking distance over one year. In DMD, longitudinal SomaScan profiling of samples collected within FOR-DMD identified proteins including RGMA, ART3, ANTXR2 and CFB whose abundance was associated with functional performance across patients and with functional change within patients. Protein-containing multivariate models improved prediction relative to models based on age and corticosteroid regimen alone. Reassessment in FOR-DMD and CINRG Duchenne Natural History Study (DNHS) cohorts using an antibody-based suspension bead array platform showed that longitudinal associations were more reproducible than cross-sectional associations. CAPNS1 and DLD were associated with change in 10MRWV in both cohorts at the same serum dilution, and were prioritised for further assay development.
The later studies addressed molecular identity and assay definition. A quantitative sandwich immunoassay was developed against a circulating titin fragment. Its abundance reflected disease severity in DMD and BMD and was associated with muscle dystrophin or microdystrophin expression in gene-therapy-treated mdx mice, supporting further evaluation as an indirect pharmacodynamic biomarker. Separately, targeted mass spectrometry detected dystrophin-derived peptides in healthy human plasma, while a dystrophin-targeted bead array showed reduced dystrophin-related signal in DMD compared with carriers and healthy controls. These findings provide complementary proof-of-principle evidence that material derived from dystrophin can be measured in blood.
Together, these studies do not establish a single clinically qualified biomarker. They provide a prioritised set of candidates, an assay-defined TTN-fragment measurement, proof-of-principle plasma dystrophin detection and a staged framework linking context of use, longitudinal clinical evidence, cross-cohort robustness, orthogonal confirmation and molecular characterisation. This fra- mework supports the continued development of minimally invasive biomark- ers for disease monitoring and treatment-response assessment in rare neuro- muscular disorders.